Journal: Oncology Letters
Article Title: Identification of prognostic biomarkers associated with metastasis and immune infiltration in osteosarcoma
doi: 10.3892/ol.2021.12441
Figure Lengend Snippet: Clinical validation of tumor-infiltrating immune cells and target genes in clinical osteosarcoma tissues with and without metastasis. (A) Representative images and (B) statistical analyses of immunohistochemical staining for CD56, CD22, CD86, CD163, CD11B, GATA3, LPAR5, EVI2B, RIAM and CFH . Magnification, ×200. *P<0.05.
Article Snippet: The following primary antibodies were used for immunostaining: CD56 bright natural killer (NK) cell-specific antibody CD56 (1:100; cat. no. 14255-1-AP; ProteinTech Group, Inc.), immature B cell-specific antibody CD22 (1:200; cat. no. 21894-1-AP; ProteinTech Group, Inc.), M1 macrophage-specific antibody CD86 (1:100; cat. no. DF6332; Affinity Biosciences), M2 macrophage-specific antibody CD163 (1:100; cat. no. 16646-1-AP; ProteinTech Group, Inc.), neutrophil-specific antibody CD11B (1:200; cat. no. bs-1014R; BIOSS), GATA3 (1:200; cat. no. 10417-1-AP; ProteinTech Group, Inc.), LPAR5 (1:500; cat. no. bs-15366R; BIOSS), EVI2B (1:50; cat. no. 24891-1-AP; ProteinTech Group, Inc.), RIAM (1:100; cat. no. 13500-1-AP; ProteinTech Group, Inc.) and CFH (1:400; cat. no. bs-9525R; BIOSS).
Techniques: Biomarker Discovery, Immunohistochemical staining, Staining